Difference between revisions of "Tubulocystic carcinoma of the kidney"

Jump to navigation Jump to search
Line 94: Line 94:
*RCC +ve.
*RCC +ve.
*Vimentin +ve.
*Vimentin +ve.
*AMACR +ve.
*[[AMACR]] +ve.
*CK7 -ve/+ve (focally in 2/3 tumours<ref name=pmid23157747>{{Cite journal  | last1 = Zhang | first1 = SH. | last2 = Shi | first2 = SF. | last3 = Huang | first3 = SF. | last4 = Zhang | first4 = YN. | last5 = Zheng | first5 = YY. | last6 = Chen | first6 = GY. | title = [Clinical and pathologic features of tubulocystic carcinoma of kidney]. | journal = Zhonghua Bing Li Xue Za Zhi | volume = 41 | issue = 8 | pages = 543-6 | month = Aug | year = 2012 | doi =  | PMID = 23157747 }}</ref>).
*[[CK7]] -ve/+ve (focally in 2/3 tumours<ref name=pmid23157747>{{Cite journal  | last1 = Zhang | first1 = SH. | last2 = Shi | first2 = SF. | last3 = Huang | first3 = SF. | last4 = Zhang | first4 = YN. | last5 = Zheng | first5 = YY. | last6 = Chen | first6 = GY. | title = [Clinical and pathologic features of tubulocystic carcinoma of kidney]. | journal = Zhonghua Bing Li Xue Za Zhi | volume = 41 | issue = 8 | pages = 543-6 | month = Aug | year = 2012 | doi =  | PMID = 23157747 }}</ref>).


Notes:
Notes:
48,466

edits

Navigation menu